Exclusive Summary

• - Fully off-patent globally; broad generic entry since 2019 with no meaningful patent barriers, enabling rapid scale-up.
• - Core therapy for CKD-related hyperphosphatemia, addressing a steady need in 4M+ dialysis patients and additional late-stage CKD patients worldwide.
• - Aligned with KDIGO guidance prioritizing non-calcium binders in patients at risk of hypercalcemia or vascular calcification, with carbonate offering better GI/acid–base profile.
• - US-FDA GMP and US/Philippines registrations support fast-track filings via reliance pathways and de-risked quality for distributors.
• - Delivers 70–90% price reduction versus originator, improving affordability and payer acceptance across tender/insurance settings.